Discern Health Staff Present At National Comprehensive Cancer Network

April 2018

Discern successfully submitted an abstract titled “Measuring the Quality of Personalized Medicine: A Review of the Current Approach and Vision for the Future” to the National Comprehensive Cancer Network (NCCN) as part of our work with the Pharmaceutical Research and Manufacturers of America (PhRMA) on quality measurement for personalized medicine. In March, Discern Director Russ Montgomery and Project Manager Kaitlyn Whiton attended and presented a poster of the work at the 2018 NCCN Annual Conference in Orlando, Fl.

The abstract and poster reviewed existing oncology quality measures to identify specific challenges in the current measures and to recommend new approaches. Among our recommendations was the need for prioritizing and developing cross-cutting, patient-centered oncology measures that are applicable across cancer types.

View the NCCN Poster

Discern expands Health Economics and Outcomes Research (HEOR) capabilities for Life Sciences clients

September 2018 Health economics and outcomes research (HEOR) has long been important for health care market access outside the U.S., but it is increasingly being utilized in the U.S. as part of the mo...
Learn More



Contact Us


Guy D’Andrea Speaks About Innovative Payment Models

September 2018 Click here to view the VIDEO...
Learn More